Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...

Instead of making life easier for medical device companies, the FDA’s new wearables guidance makes the market more complex.

Fortem Technologies, the global leader in airspace security and counter-drone solutions, today announced it has completed what it believes is the first autonomous 5-vs-5 drone intercept with safe ...

Shore Group, a traditional outsource staffing provider since 2006, today announced it has completed a three-year transformation into an AI-enabled operations company and launched Shore Digital ...

This article discusses the best growth stocks to buy right now.

Dexcom announced a new wave of AI-powered features designed to help users understand how food and daily habits affect their metabolic health.

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something important about this glucose monitoring specialist? DexCom shares last closed ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...